28 Result(s)
-
Article
Open AccessMulti-omic profiling reveals discrepant immunogenic properties and a unique tumor microenvironment among melanoma brain metastases
Melanoma brain metastases (MBM) are clinically challenging to treat and exhibit variable responses to immune checkpoint therapies. Prior research suggests that MBM exhibit poor tumor immune responses and are e...
-
Article
Open Access31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts
-
Article
Open Access31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one
-
Article
Open Access29th Annual meeting of the Society for Immunotherapy of Cancer (SITC)
The 29th annual meeting of the Society for Immunotherapy of Cancer (SITC) was held November 7-9, 2014 in National Harbor, MD and was organized by Dr. Arthur A. Hurwitz (National Cancer Institute), Dr. Kim A. Marg...
-
Article
Open AccessCITN-06: a Phase I/expansion trial of alt-803, an IL-15 superagonist, in patients with advanced melanoma
-
Article
Open AccessAdoptively transferred melanoma-reactive CTL primed in the presence of IL-21 and transferred with concurrent CTLA4 blockade results in enhanced CTL persistence and tumor regression
-
Article
Open AccessThe Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma
Immunotherapy is associated with durable clinical benefit in patients with melanoma, and this consensus statement outlines recommendations for its use. The panel has based their guidance on the available evide...
-
Article
Tumor-Infiltrating Lymphocytes in Melanoma
Adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) is arguably the most effective treatment for patients with metastatic melanoma. With higher response rates than ipilimumab or IL-2, and longer d...
-
Article
Adoptive T-Cell Therapy of Melanoma Using Designer T-Cell Receptors
-
Article
Treatment of Advanced Melanoma with Immunological Checkpoint Block
-
Article
Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase I trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spinal cord tumors
This study was designed to ascertain the dose-limiting toxicities (DLT) and maximally tolerated doses of the combination of fixed-dose tamoxifen and carboplatin, with escalating doses of topotecan, and to dete...
-
Article
IL-2 in the therapy of melanoma and other malignancies
IL-2 as a single agent has been approved for use in both renal cancer and melanoma, and it has achieved widespread use in these malignancies for selected patients with metastatic disease. For these diseases, a...
-
Article
Oblimersen and α-interferon in metastatic renal cancer: a phase II study of the California Cancer Consortium
Oblimersen is an 18-base oligodeoxynucleotide encoding antisense to the gene for bcl-2, an anti-apoptotic protein that is upregulated in renal and other cancers. This study was designed to evaluate the combina...
-
Article
A phase I study of oxaliplatin in combination with gemcitabine: correlation of clinical outcome with gene expression
Oxaliplatin has in vitro activity similar to or higher than other platinum agents. Preclinically, gemcitabine has demonstrated synergy when combined with platinum compounds. These facts formed the rationale fo...
-
Article
Phase I trial of menadiol diphosphate (vitamin K3) in advanced malignancy
Based on the activity of menadione (M) in the human tumor stem cell assay, we conducted a phase I trial of M in patients with advanced cancer. Forty patients (19 men, 21 women) were treated with 90 courses of ...
-
Article
Phase II trial of carboplatin and infusional cyclosporine in platinum-resistant recurrent ovarian cancer
To determine the response rate to 26-h continuous infusion cyclosporine A (CSA) combined with a fixed dose level of carboplatin (CBDCA) in patients with recurrent ovarian cancer, and to determine the effect of...
-
Article
A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer
3-Aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP), a new and potent inhibitor of ribonucleotide reductase (RR), increases the cellular uptake, DNA incorporation, and cytotoxicity of gemcitabine in tumo...
-
Article
Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96 h for the treatment of advanced malignancies
Dexrazoxane administration prior to short infusion doxorubicin prevents anthracycline-related heart damage. Since delivery of doxorubicin by 96-h continuous intravenous infusion also reduces cardiac injury, we...
-
Article
Phase I study of cisdiamminedichloroplatinum in combination with azidothymidine in the treatment of patients with advanced malignancies
Azidothymidine (AZT, zidovudine) has been shown to reverse cisplatin resistance in cell culture. This phase I study was performed to determine the maximally tolerated dose (MTD) and dose-limiting toxicities of...
-
Article
Phase I pharmacodynamic study of time and sequence dependency of hydroxyurea in combination with gemcitabine: a California Cancer Consortium Trial
Preclinical studies in our laboratory have demonstrated that prior exposure to hydroxyurea increases the percentage of cells in S phase, enhancing the cytotoxicity of subsequent gemcitabine treatment in human...
